View Item 

Show simple item record

Management of haemophilia B patients with inhibitors and anaphylaxis
dc.contributor.authorLee, C. A.en_US
dc.contributor.authorKessler, C. M.en_US
dc.contributor.authorVaron, D.en_US
dc.contributor.authorMartinowitz, U.en_US
dc.contributor.authorHeim, M.en_US
dc.contributor.authorWarrier, I.en_US
dc.date.accessioned2012-10-02T17:20:06Z
dc.date.available2012-10-02T17:20:06Z
dc.date.issued1998-07en_US
dc.identifier.citationLee, C. A.; Kessler, C. M.; Varon, D.; Martinowitz, U.; Heim, M.; Warrier, I. (1998). "Management of haemophilia B patients with inhibitors and anaphylaxis." Haemophilia 4(4). <http://hdl.handle.net/2027.42/93681>en_US
dc.identifier.issn1351-8216en_US
dc.identifier.issn1365-2516en_US
dc.identifier.urihttps://hdl.handle.net/2027.42/93681
dc.publisherWiley Periodicals, Inc.en_US
dc.publisherBlackwell Science Ltden_US
dc.subject.otherRFVIIaen_US
dc.subject.otherHemophilia Ben_US
dc.subject.otherFIX Inhibitoren_US
dc.subject.otherAnaphylaxisen_US
dc.titleManagement of haemophilia B patients with inhibitors and anaphylaxisen_US
dc.typeArticleen_US
dc.rights.robotsIndexNoFollowen_US
dc.subject.hlbsecondlevelOncology and Hematologyen_US
dc.subject.hlbtoplevelHealth Sciencesen_US
dc.description.peerreviewedPeer Revieweden_US
dc.contributor.affiliationotherWayne State University and Hemophilia Treatment Center, Children's Hospital of Michigan, Detroit, MI, USAen_US
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/93681/1/j.1365-2516.1998.440574.x.pdf
dc.identifier.doi10.1046/j.1365-2516.1998.440574.xen_US
dc.identifier.sourceHaemophiliaen_US
dc.identifier.citedreferenceWarrier I, Ewenstein BM, Koerper MA, Shapiro A, et al. Factor IX inhibitors and anaphylaxis in haemophilia B. J Pediatr Hematol Oncol 1997; 19: 23 – 7.en_US
dc.identifier.citedreferenceLenk H, Bierback U, Schille R. Inhibitor to FIX in haemophilia B and nephrotic syndrome in the course of immune tolerance treatment. Haemophilia 1996; 2 ( Suppl 1 ): 104.en_US
dc.identifier.citedreferenceEwenstein BM, Takemoto C, Warrier I, Lusher J, Saidi P, Eisele J, et al. Nephrotic syndrome as a complication of immune tolerance in hemophilia B. Blood 1997; 89: 115 – 6.en_US
dc.identifier.citedreferenceCollins PW, Fields P, Goldman E, Lee CA and Pasi KJ. The use of rFVIIa to treat a factor IX inhibitor following anaphylaxis with factor IX concentrate. Blood Coagulation and Fibrinolysis 1995; 6: 177.en_US
dc.identifier.citedreferenceBergman F, Vester U, Rose M, Hoyer PF, Bohn U, Barthels M. Behandlungsaltervativen bei Hemmorkörperhämophilie B: Erfahrungen mit dem Einsatz von rekombinatem Faktor VIIa (rFVIIa). In: Scharrer I, Schramm W, eds. Hämophilie‐Symposium. Hamburg, Berlin, Heidelberg: Springer Verlag 1994; 126 – 9.en_US
dc.identifier.citedreferenceWarrier I, Lusher JM. Recombinant (r) factor VIIa (Novo‐Seven) is the most appropriate treatment for children with hemophilia B complicated by inhibitor antibodies and anaphylaxis to FIX containing products. Blood 1996; 88 ( Suppl 1 ): 442a.en_US
dc.identifier.citedreferenceWarrier I, Ewenstein BM, Koerper MA, et al. FIX inhibitor and anaphylaxis in haemophilia B correspondence. Haemophilia, 1996; 2: 259 – 61.en_US
dc.identifier.citedreferencePollmann H. A haemophilia B patient with complete factor IX gene deletion and a high titer antibody against FIX. Haemophilia 1996; 2 ( Suppl 1 ): 72.en_US
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
j.1365-2516.1998.440574.x.pdf
Size:
341.6KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.